Cellectar Biosciences Registers 52M Shares for Resale; Going Concern Doubt

Cellectar Biosciences filed an S-1/A registration statement for the resale of up to 51,998,413 shares of common stock by selling stockholders. These shares originate from a private placement that closed on May 6, 2026, and include shares issuable upon the exercise of various warrants. Concurrently, the company conducted a registered direct offering and appointed Andrew Gu to its Board of Directors as part of an agreement with Nantahala Capital Management. The company will not receive proceeds from the resale but will from warrant exercises, and noted its cash balance of $13.2 million as of December 31, 2025, is sufficient only into Q2 2027, raising going concern doubts.